PGEN earnings analysis
What we found in PGEN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Precigen's first meaningful commercial Papzimeos ramp transformed Q2 revenue to $54.978 million from $0.856 million a year earlier and generated $20.071 million of net income, or $0.05 diluted EPS. The resulting 94.9% gross margin and 41.2% operating margin are strong, though management cautions that gross margin should normalize after approximately $9 million of pre-launch inventory is sold in Q3 2026. The principal counterweight is working capital: 127-day payment terms and launch-related receivables/inventory drove $61.636 million of six-month operating cash outflow despite reported profitability.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Papzimeos drove $54.1M revenue increase
- Q2 revenue rose to $54.978 million from $0.856 million in Q2 2025, an increase of $54.122 million. Product revenue was $53.262 million, with $53.1 million attributed to Papzimeos sales following its August 2025 approval and launch.
- Profitability inflection in Q2
- Operating income was $22.642 million, versus an operating loss of $31.764 million a year earlier, producing a 41.2% operating margin. Net income was $20.071 million versus a $26.642 million loss, and diluted EPS was $0.05 versus a $0.09 loss.
- Initial gross margin reached 94.9%
- Gross profit was $52.173 million on $54.978 million of revenue, equating to a 94.9% gross margin. Management expects normalized gross margins to stabilize in the high-80% to low-90% range once pre-launch inventory has been sold.
- R&D fell while commercial spending scaled
- R&D expense declined $4.206 million, or 36.6%, to $7.282 million, while SG&A rose $6.116 million, or 37.9%, to $22.249 million as commercialization activities expanded. The expense mix reflects the shift from pre-approval manufacturing R&D to commercial inventory and selling costs.
- Management sees at least one year of runway
- Cash, cash equivalents and investments totaled $38.7 million at June 30, 2026. Management believes this liquidity plus anticipated Papzimeos receivable collections will support operations for at least one year from the filing date.
- Exclusivity supports commercial opportunity
- Papzimeos received seven years of orphan-drug exclusivity through August 14, 2032. Management estimates approximately 27,000 adult U.S. patients are living with recurrent respiratory papillomatosis.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Receivables drove substantial operating cash use
- Operating cash flow was negative $61.636 million in the first six months of 2026 despite $12.142 million of net income, as working-capital changes consumed $83.2 million. Papzimeos customer payment terms are 127 days, increasing collections and liquidity risk during launch.
- Debt creates interest-rate and cash burden
- Long-term debt totaled $93.9 million at June 30, 2026, and contractual cash interest payable was $35.024 million. A 100-basis-point increase in SOFR would raise annual interest expense by approximately $1.0 million.
- Revenue is concentrated in Papzimeos
- Papzimeos represented $53.1 million of the company's $54.978 million Q2 revenue. Management expects the majority of foreseeable future revenue to come from Papzimeos, leaving results highly dependent on adoption, payer coverage, and collections for one product.
- Gross margin should normalize after Q3
- Management expects to finish selling pre-launch inventory in Q3 2026 and says gross margins will decline from current levels as that inventory is exhausted, stabilizing only in the high-80% to low-90% range. Existing pre-launch inventory represents approximately $9 million of estimated future net revenue.
- Sustained cash generation remains unproven
- The company reported an accumulated deficit of $2.3 billion as of June 30, 2026 and states it may need debt, royalty, equity, or strategic financing until it regularly generates positive operating cash flow. It also had $5.4 million of unincurred third-party R&D commitments.
- No risk-factor updates versus annual report
- No material risk-factor additions or changes were reported versus the 2025 Annual Report. The filing explicitly states there were no additional material updates to risk factors.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.05
- Gross margin
- 94.9%
- Operating margin
- 41.2%
- Segment
- Product revenue: $53.262 million
- Segment
- Service revenue: $1.716 million
What they said about what is next.
No numerical revenue or EPS guidance was provided in the 10-Q. Management expects Papzimeos gross margins to stabilize in the high-80% to low-90% range after pre-launch inventory is sold, which it expects to occur in Q3 2026; it also states existing liquidity plus anticipated Papzimeos receivable collections should fund operations for at least one year from the filing date.
The filing reads better than the one before it.
What came before.
- 10-Q · May 13, 2026
- Precigen's Q1 2026 report shows a substantial turnaround with revenues exceeding $23 million driven by the recent commercial launch of Papzimeos, resulting in a significant net loss reduction of 85.4% compared to last…
- 10-K · March 25, 2026
- Precigen transitioned to a commercial-stage company after the FDA granted full approval to Papzimeos in August 2025 and saw a clear revenue and margin inflection in H2 2025. Revenue accelerated to multi‑million dollar…
- 10-Q · August 14, 2024
- Precigen reported quarterly revenue of $717,000 for the three months ended June 30, 2024, a 59.4% decline versus $1,767,000 in Q2 2023, and GAAP net loss worsened to $(58,792,000) versus $(20,319,000) a year earlier.…
- 10-K · March 19, 2024
- Precigen emphasizes its proprietary platforms (UltraCAR-T, AdenoVerse, ActoBiotics) and internal manufacturing capability (UltraPorator) while prioritizing disciplined portfolio management and rapid advancement of lead…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PGEN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever